Literature DB >> 10086967

Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation.

A Nabar1, L M Rodriguez, C Timmermans, A van den Dool, J L Smeets, H J Wellens.   

Abstract

BACKGROUND: The goal of this study was to test the hypothesis that the occurrence of atrial fibrillation (AF), in at least some patients with coexisting type I atrial flutter (AFL), is based on macro-reentry around the tricuspid valve orifice, including the right atrial (RA) isthmus, by evaluation of AF recurrences after successful ablation of AFL. METHODS AND
RESULTS: Eighty-two consecutive patients with type I AFL, with or without concomitant AF, underwent radiofrequency ablation (RFA) of the RA isthmus by an anatomical approach. The results were analyzed in 4 groups of patients: group 1 (only AFL; 29 patients), group 2 (AFL >AF; 22 patients), group 3 (AF >AFL; 15 patients), and group 4 (developing AFL while receiving class IC antiarrhythmic drug therapy for AF, the "class IC atrial flutter"; 16 patients). In all groups, RFA of type I AFL was performed with a high (>/=93%) procedural success rate. In group 1, only 2 patients (8%) had AF after (18+/-14 months) AFL ablation. These figures were 38% (20+/-14 months) and 86% (13+/-8 months) in groups 2 and 3, respectively. Group 4 patients (4+/-2 months) had a 73% freedom of AF recurrences with continuation of the class IC agent.
CONCLUSIONS: The low incidence of new AF during long-term follow-up after RFA of type I AFL makes it unlikely that radiofrequency lesions promote the development of AF. The impact of isthmus ablation on AF recurrences differs according to the clinically predominant atrial arrhythmia and suggests a possible role of the RA isthmus in the occurrence of AF in some patients. Ablation of class IC atrial flutter in patients with therapy-resistant AF is a novel approach to management of this patient subset. Careful classification of AF patients plays a role in the selection of the site of ablation therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10086967     DOI: 10.1161/01.cir.99.11.1441

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

Review 1.  Science, medicine, and the future: Radiofrequency ablation for atrial fibrillation.

Authors:  N R Grubb; S Furniss
Journal:  BMJ       Date:  2001-03-31

2.  Atrial Flutter.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-08

Review 3.  Pilsicainide for atrial fibrillation.

Authors:  Koichiro Kumagai; Hideko Nakashima; Hideaki Tojo; Tomoo Yasuda; Hiroo Noguchi; Naomichi Matsumoto; Masahiro Ogawa; Keijiro Saku
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Endurance Sport Practice and Atrial Fibrillation.

Authors:  Naiara Calvo; Lluis Mont
Journal:  J Atr Fibrillation       Date:  2010-10-22

Review 5.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 6.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

Review 7.  Management of atrial flutter.

Authors:  E Kongsgaard; H Aass
Journal:  Curr Cardiol Rep       Date:  2000-07       Impact factor: 2.931

8.  Incidence and predictive factors of atrial fibrillation after ablation of typical atrial flutter.

Authors:  Valérie Laurent; Laurent Fauchier; Bertrand Pierre; Caroline Grimard; Dominique Babuty
Journal:  J Interv Card Electrophysiol       Date:  2008-11-04       Impact factor: 1.900

9.  Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics.

Authors:  W Anné; R Willems; N Van der Merwe; F Van de Werf; H Ector; H Heidbüchel
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

10.  Long term follow up of radiofrequency catheter ablation of atrial flutter: clinical course and predictors of atrial fibrillation occurrence.

Authors:  E Bertaglia; F Zoppo; A Bonso; A Proclemer; R Verlato; L Corò; R Mantovan; D D'Este; F Zerbo; P Pascotto
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.